Teva UK launches generic latanoprost

January 25, 2012

Teva UK Ltd. has launched a generic version of latanoprost 0.005% eye drops solution (Xalatan, Pfizer). Latanoprost is indicated for the treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension.

Castleford, England-Teva UK Ltd. has launched a generic version of latanoprost 0.005% eye drops solution (Xalatan, Pfizer).

Latanoprost is indicated for the treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension.

“As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues to lead with strong product launches and patent expired products,” said Kim Innes, Teva’s commercial director. “This is our inaugural product launch for 2012 and our first day-one patent expiry of the year.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Content:

News